Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1086/324190 | DOI Listing |
Int J Cardiol Heart Vasc
February 2025
Department of Cardiology. University Hospital Alvaro Cunqueiro, Vigo, Spain. Galicia Sur Health Research Institute (IIS Galicia Sur). SERGAS-UVIGO.
Introduction And Objectives: Percutaneous left atrial appendage occlusion (LAAO) is a viable option to mitigate bleeding and stroke risks in patients with atrial fibrillation (AF) who are not eligible for oral anticoagulation. Its safety and efficacy in cancer patients remain unclear due to their exclusion from trials. This study aimed to compare short- and long-term LAAO outcomes between cancer and non-cancer patients.
View Article and Find Full Text PDFBiofilm
December 2024
Department of Biomaterials, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Biodegradable polymeric coatings are being explored as a preventive strategy for orthopaedic device-related infection. In this study, titanium surfaces (Ti) were coated with poly-D,L-lactide (PDLLA, (P)), polyethylene-glycol poly-D,L-lactide PEGylated-PDLLA, (PP20)), or multi-layered PEGylated-PDLLA (M), with or without 1 % silver sulfadiazine. The aim was to evaluate their cytocompatibility, resistance to biofilm formation, and their potential to enhance the susceptibility of any biofilm formed to antibiotics.
View Article and Find Full Text PDFTransplant Direct
February 2025
Hospital do Rim, Fundação Oswaldo Ramos, São Paulo, Brazil.
Background: Although multifaceted control intervention actions (bundles) are highly effective in reducing the risk of device-related healthcare-associated infections (d-HAIs), no studies have explored their impact on the outcomes of kidney transplant recipients (KTRs) or the extent of risk reduction achievable through the bundle implementation.
Methods: Seven hundred ninety-eight prevalent KTRs admitted to the intensive care unit (ICU) requiring invasive devices were included: 449 patients from the bundle preimplementation period and 349 from the postimplementation period. The primary outcome was mortality within 90 d of ICU admission.
Eur J Heart Fail
January 2025
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
Aims: As patients experience longer survival on HeartMate 3 left ventricular assist devices, there is a need to characterize long-term risks of adverse outcomes more precisely. This study characterized temporal variations in risks of mortality and adverse outcomes in patients with a HeartMate 3.
Methods And Results: From October 2015 to January 2023, 431 HeartMate 3 devices were implanted at Cleveland Clinic.
Kardiol Pol
January 2025
Department of Cardiology, Division of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Silesian Center for Heart Diseases, Zabrze, Poland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!